Current Oncology · 7 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This systematic review analyzed 83 studies on 21,034 participants to investigate the association between Mean Platelet Volume and 12 types of cancer. It found that MPV is often elevated in certain cancers like gastric and breast cancer, and may serve as a potential biomarker for diagnosis and prognosis, though further research is needed.
This systematic review identified 83 studies involving 21,034 participants with 12 different cancer types, published between 2010 and 2022, to examine the relationship between Mean Platelet Volume (MPV) and cancer diagnosis, prognosis, severity, and metastasis. Most studies in gastric, breast, endometrial, thyroid, and lung cancer documented elevated MPV in cancer patients compared to controls. For colon and lung cancer, several studies indicated an unfavorable role of increased MPV regarding mortality. Data were less consistent for other cancers like esophageal, ovarian, and colon cancer, and reduced MPV was seen in renal cell and gallbladder cancer. The authors conclude MPV is a potential biomarker for cancer diagnosis and treatment optimization. Key limitations include the predominantly retrospective study designs, small sample sizes, heterogeneous methodologies, and the fact that most studies were from China and Turkey, limiting generalizability. The review did not provide quantitative MPV level comparisons.
